Latest News for: acaai
Edit
Index-Journal
23 Nov 2025
ModuleMD Showcases Advanced AI-Driven Allergy Solutions at ACAAI 2025
22, 2025 /PRNewswire/ -- This November at the ACAAI ...
Edit
Press Release dated November 7, 2025: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review (Form 6-K) (Sanofi SA)
Public Technologies 18 Nov 2025
Edit
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (Form 8-K) (Nektar Therapeutics)
Public Technologies 10 Nov 2025
Edit
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting (Pharvaris NV)
Public Technologies 10 Nov 2025
... Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI), including data from two oral presentations and six posters, which took place from November 6-10, 2025, in Orlando, Fla.
Edit
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Pharmiweb 10 Nov 2025
ACAAI ... These are the first-ever positive phase 3 results specifically in AFRS and will be shared today at the American College of Allergy, Asthma and Immunology (ACAAI) 2025 Annual Scientific Meeting, Orlando, FL, US.
Edit
Napa Valley Register
09 Nov 2025
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI ...
Edit
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
PR Newswire 08 Nov 2025
NKTR) today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking oral abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting.
Edit
Lincoln Journal Star
07 Nov 2025
ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut
SUZHOU, China, Nov.
Edit
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review (Sanofi SA)
Public Technologies 07 Nov 2025
ACAAI ... These are the first-ever positive phase 3 results specifically in AFRS and will be shared today at the American College of Allergy, Asthma and Immunology (ACAAI) 2025 Annual Scientific Meeting, Orlando, FL, US.
- 1